Diagnostic and treatment provider Somnomed Limited (ASX:SOM) has improved its third quarter sales by 28 per cent to $6.5 million. The result was aided by sales records in US markets and the growth adds to gains made in the first half of the year. Executive Chairman Dr Peter Neustadt says this is the highest volume growth achieved in a March quarter for the last three years.
Investors responded well to the announcement with the company’s share price jumping more than 15 per cent in morning trade.
Somnomed made a net profit of $8,000 in the first half of the 2014 financial year.
